This summary table contains detailed information about research studies. Summary tables offer an informative look at the science behind many breast cancer guidelines and recommendations. However, they should be viewed with some caution. In order to read and interpret research tables successfully, it is important to understand some key concepts. Learn how to read a research table.
Introduction: Tamoxifen improves overall survival for women with estrogen receptor-positive breast cancer.
Results from the Early Breast Cancer Trialists’ Collaborative Group pooled analysis showed tamoxifen use for five years increased overall survival. Tamoxifen increased survival in women with lymph node-negative tumors and those with lymph node-positive tumors. The benefits of tamoxifen were not limited by a woman’s age or past treatment with chemotherapy.
Learn more about tamoxifen.
Learn about the strengths and weaknesses of different types of studies.
Study selection criteria: Early Breast Cancer Trialists' Collaborative pooled analysis.
Pooled AnalysisEarly Breast Cancer Trialists' Collaborative Group [1-2]
15-Year Breast Cancer Survival*
Percent Surviving—No Tamoxifen
Absolute Improvementin Survivalwith Tamoxifen
Tamoxifen use for 5 years
10-Year Overall Survival‡
Lymph node negative
Lymph node positive
15-Year Overall Survival‡
* Combined data from 20 randomized clinical trials that together included 21,457 women † Statistically significant improvement ‡ Combined data from 44 randomized clinical trials that together included 33,209 women
Discover the different ways you can help